{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Cumberland+Pharmaceuticals",
    "query": {
      "sponsor": "Cumberland Pharmaceuticals",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 59,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Cumberland+Pharmaceuticals&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Cumberland+Pharmaceuticals&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T13:27:22.830Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02013141",
      "title": "Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gram-Positive Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2014-12",
      "completion_date": "2021-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-24",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013141"
    },
    {
      "nct_id": "NCT00939913",
      "title": "Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nephropathy"
      ],
      "interventions": [
        {
          "name": "intravenous NAC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ochsner Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2007-01",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2009-09-18",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939913"
    },
    {
      "nct_id": "NCT03340675",
      "title": "Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy Cardiomyopathy",
        "Cardiomyopathy, Dilated"
      ],
      "interventions": [
        {
          "name": "Ifetroban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "7 Years and older · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2020-10-19",
      "completion_date": "2026-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03340675"
    },
    {
      "nct_id": "NCT01436500",
      "title": "Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatorenal Syndrome"
      ],
      "interventions": [
        {
          "name": "Ifetroban Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2011-10",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436500"
    },
    {
      "nct_id": "NCT00780962",
      "title": "N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Radiocontrast Nephropathy"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine (NAC)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium-chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 399,
      "start_date": "2007-10-16",
      "completion_date": "2010-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00780962"
    },
    {
      "nct_id": "NCT00379847",
      "title": "An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyponatremia"
      ],
      "interventions": [
        {
          "name": "conivaptan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 251,
      "start_date": "2004-02",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 7,
      "location_summary": "Tuscon, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Petoskey",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379847"
    },
    {
      "nct_id": "NCT00091819",
      "title": "Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Staphylococcal Skin Infection"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 862,
      "start_date": "2005-01",
      "completion_date": "2006-06",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 1,
      "location_summary": "National City, California",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00091819"
    },
    {
      "nct_id": "NCT03962855",
      "title": "Thromboxane Receptor Antagonist to Improve Endothelial Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Vascular Dilation"
      ],
      "interventions": [
        {
          "name": "Ifetroban Sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Rade",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 57,
      "start_date": "2019-09-20",
      "completion_date": "2022-11-15",
      "has_results": true,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03962855"
    },
    {
      "nct_id": "NCT00107952",
      "title": "Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 761,
      "start_date": "2005-02",
      "completion_date": "2007-07",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 1,
      "location_summary": "Springfield, Massachusetts",
      "locations": [
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107952"
    },
    {
      "nct_id": "NCT00889538",
      "title": "Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism",
        "Severe Behavior Disorder"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "glutathione",
          "type": "DRUG"
        },
        {
          "name": "glutathione, vit C and NAC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-04",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2016-12-07",
      "last_synced_at": "2026-10-10T13:27:22.830Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00889538"
    }
  ]
}